4 results match your criteria: "Inserm U991 University of Rennes 1[Affiliation]"
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
Inflamm Bowel Dis
May 2015
*Department of Hepato-Gastroenterology, University Hospital of Rennes, Pontchaillou and Inserm U991 University of Rennes 1, Rennes, France; †Department of Hepato-Gastroenterology, University Hospital of Bordeaux, Hôpital Haut-Lévêque, Bordeaux, France; ‡Department of Hepato-Gastroenterology, University Hospital Lyon-Sud, University Claude Bernard Lyon 1, Lyon, France; §Department of Gastroenterology and Clinical Nutrition, University Hospital of Nice, University of Nice Sophia Antipolis, Nice, France; ‖Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France; ¶Institut des Maladies de l'appareil Digestif (IMAD), University Hospital of Nantes, Nantes, France; and **Inserm, U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Université de Lorraine, Vandoeuvre-les-Nancy, France.
Background: In case of a loss of response to adalimumab, some patients with Crohn's disease may derive benefit from increasing the dosing frequency to 40 mg weekly. Efficacy and safety of adalimumab 80 mg weekly remain unknown.
Methods: From February 2011 to September 2012, all adults who had active Crohn's disease, defined at least by Crohn's disease activity index >150 and 1 objective sign of inflammation, and required an adalimumab dose escalation to 80 mg weekly were enrolled in a prospective multicenter cohort study.
Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis.
Inflamm Bowel Dis
February 2014
*Division of Gastroenterology, University of California San Diego, San Diego, California; and †Department of Hepato-Gastroenterology, University Hospital of Rennes, Pontchaillou, Inserm U991 University of Rennes 1, Rennes, France.
Background: Mucosal healing (MH) as a treatment target for ulcerative colitis is of growing interest because it is associated with improved clinical outcomes. However, the feasibility and probability of reaching MH in clinical practice is unknown. We therefore evaluated the feasibility of "treating to target" according to endoscopic findings to reach MH.
View Article and Find Full Text PDFEndoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease.
Clin Gastroenterol Hepatol
June 2014
Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address:
Background & Aims: Mucosal healing has been proposed as a goal for treatment because it is associated with improved clinical outcomes of patients with Crohn's disease (CD). However, little is known about the feasibility or probability of achieving mucosal healing in clinical practice. We evaluated the feasibility of treating patients to achieve mucosal healing based on endoscopic evaluation (treating to target).
View Article and Find Full Text PDFLong-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Clin Gastroenterol Hepatol
August 2013
Department of Hepato-Gastroenterology, University Hospital of Rennes, Pontchaillou, Inserm U991 University of Rennes 1, Rennes, France.
Background & Aims: Little is known about the long-term efficacy of infliximab for patients with fistulizing perianal Crohn's disease. We evaluated outcomes and predictors of outcomes in these patients.
Methods: The medical records of 156 patients treated with infliximab for fistulizing perianal Crohn's disease at 2 referral centers from 1999 through 2010 were reviewed through September 2011.